Developing a Cell-Based High-Throughput Screening (HTS) Assay for Antibody-Mediated Amyloid-Beta Clearance

Authors

• Tran Vo '27, DePauw University
• Lucille Whyman, Purdue University
• June Javens-Wolfe, Indiana Bioscience Research Institute (IBRI)

Files

Document Type

Poster

Publication Date

Fall 10-1-2026

Abstract

Antibody therapeutics targeting amyloid-beta (Aβ), such as Aducanumab and Lecanemab, are among the first Alzheimer's disease treatments to show clinical potential, with efficacy thought to depend partly on Fc receptor-mediated immune clearance of Aβ plaques. Testing new antibody variants in mouse models is slow and expensive, so TREAT-AD's ADHTS core develops cell-based assays to screen candidates earlier. This project lays the groundwork for a scalable, cell-based high-throughput screening assay of antibody-mediated Aβ clearance. We purified Fc-competent and Fc-silenced Aducanumab, confirmed its specificity for full-length Aβ, and established a live-imaging assay of Aβ uptake in microglia. Assay optimization is ongoing.

Department

Indiana Bioscience Research Institute (IBRI)

Project Mentor

Dr. June Javens-Wolfe

Funding and Acknowledgements

Funded by the Indiana Bioscience Research Institute (IBRI), TREAT-AD, and Dr. John Lechleiter.

Recommended Citation

Vo, Tran '27; Whyman, Lucille; and Javens-Wolfe, June, "Developing a Cell-Based High-Throughput Screening (HTS) Assay for Antibody-Mediated Amyloid-Beta Clearance" (2026). Annual Student Research Poster Session. 266.
https://scholarship.depauw.edu/srfposters/266